Search clinical trials for: anti-PD-1 Albumin-Bound Paclitaxel

Total 1528 results

Sun Yat-sen University

Active, not recruiting

Study of Anti-PD-1 Combined With Albumin-Bound Paclitaxel in Patients With Recurrent Cervical Cancer

Recurrent Cervical Cancer

China
Huazhong University of Science and Technology

Active, not recruiting

Nab-paclitaxel Plus PD-1 Inhibitor Versus Nab-paclitaxel as Second-line Treatment in Advanced Gastric Cancer

Gastric Cancer | GastroEsophageal Cancer

China
Lei Li

Recruiting

Immunotherapy for Recurrent Cervical Cancer Refractory to Platinum-based Chemotherapy: Multi-Center Trial

Chemotherapy | Recurrent Cervical Carcinoma | Immune Checkpoint Inhibitors | Anti-PD-1 Antibody | Persistent Advanced Cervical Carcinoma | Albumin-bound Paclitaxel

China
Huazhong University of Science and Technology
Chongqing University Cancer Hospital; Peking University People's Hospital; Qilu... and other collaborators

Recruiting

Pd-1 Antibody Combined Neoadjuvant Chemotherapy for Locally Advanced Cervical Cancer

Cervical Cancer | Uterine Cervical Cancer | Uterine Cervical Neoplasm

China
Chinese PLA General Hospital

Completed

An Open-label, Phase I/II Study of the Pan-immunotherapy in Patients With Relapsed/Refractory Ovarian Cancer

Ovarian Cancer

China
Peking University Cancer Hospital & Institute

Recruiting

Paclitaxel (Albumin-bound) Combined With Oxaliplatin and S-1 Conversion Therapy for Gastric Adenocarcinoma

Gastric Adenocarcinoma

China
Chinese PLA General Hospital

Unknown

An Open-label, Phase I/II Study of the Pan-immunotherapy in Patients With Local Advanced/Metastatic Pancreatic Cancer

Pancreatic Cancer

China
Lei Li

Completed

Immunotherapy for Recurrent Cervical Cancer Refractory to Platinum-based Chemotherapy

Chemotherapy | Recurrent Cervical Carcinoma | Immunotherapy | Anti-PD-1 Antibody | Persistent Advanced Cervical Carcinoma

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Completed

Response to Neoadjuvant Chemoimmunotherapy in Resectable Locally Advanced Oral Cancer (HNC-SYSU-005)

Oral Cancer

China
Chinese PLA General Hospital

Unknown

A Phase I/II Study of the Pan-immunotherapy in Patients With Local Advanced/Metastatic BTC

Biliary Tract Cancer (BTC)

China
Sun Yat-sen University
Shanghai Junshi Bioscience Co., Ltd.; CSPC Ouyi Pharmaceutical Co., Ltd.

Recruiting

JS001 Combined With TP as First-line Treatment for Unresectable or Advanced Small Cell Esophageal Carcinoma

Esophageal Small Cell Carcinoma

China
Shanghai Henlius Biotech

Active, not recruiting

A Clinical Study to Evaluate Efficacy and Safety of HLX10 Combined With Albumin-Bound Paclitaxel in Patients With Advanced Cervical Cancer Who Have Progressive Disease or Intolerable Toxicity After First-Line Standard Chemotherapy

Cervical Cancer

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Suspended

A Study of First-line JS001 and Nab-paclitaxel Versus Palcelbo and Nab-Paclitaxel in Participants With Advanced Recurrent or Metastatic TNBC

Triple Negative Breast Cancer

China
Lee's Pharmaceutical Limited

Active, not recruiting

A Study of Anti-PD-L1 Antibody ZKAB001 Combined With Albumin-bound Paclitaxel in Advanced Urothelial Carcinoma

Advanced Urothelial Carcinoma

China
Sun Yat-sen University

Completed

Albumin Bound Paclitaxel Plus S-1 as the First Line Chemotherapy in Advanced or Recurrent Gastric Cancer

Gastric Cancer

China
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Nab-Paclitaxel in Treating Older Patients With Locally Advanced or Metastatic Breast Cancer

Recurrent Breast Carcinoma | Stage IV Breast Cancer AJCC v6 and v7 | Stage III Breast Cancer AJCC v7 | Stage IIIA Breast Cancer AJCC v7 | Stage IIIB Breast Cancer AJCC v7 | Stage IIIC Breast Cancer AJCC v7 | Metastatic Breast Carcinoma | Locally Advanced Breast Carcinoma

United States
Anne Noonan
National Cancer Institute (NCI)

Recruiting

Biologically Optimized Infusion Schedule of Gemcitabine and Nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer

Stage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Adenocarcinoma

United States
University of Washington
National Cancer Institute (NCI); Celgene Corporation

Completed

Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Previously Treated Advanced Non-small Cell Lung Cancer

Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer

United States
Mayo Clinic
National Cancer Institute (NCI)

Withdrawn

Paclitaxel Albumin-Stabilized Nanoparticle Formulation After Cisplatin-Based Chemotherapy and Surgery in Treating Patients With High-Risk Bladder Cancer

Recurrent Bladder Urothelial Carcinoma | Stage IV Bladder Urothelial Carcinoma

United States
Sunshine Guojian Pharmaceutical (Shanghai) Co.,...

Not yet recruiting

A Phase II Study of SSGJ-707 Combination Therapy in Advanced NSCLC Patients

First-line Advanced NSCLC Patients

China
Second Affiliated Hospital, School of Medicine,...

Active, not recruiting

Neoadjuvant of Sintilimab Combined With Chemotherapy for Resectable NSCLC（neoSCORE） (neoSCORE)

Non-small Cell Lung Cancer

China
Henan Cancer Hospital

Recruiting

Camrelizumab Combined With Albumin-bound Paclitaxel and S-1 in the Treatment of Advanced Gastric Cancer

Advanced Gastric Adenocarcinoma

China
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Nab-paclitaxel and Alpelisib for the Treatment of Anthracycline Refractory Triple Negative Breast Cancer With PIK3CA or PTEN Alterations

Anatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic... and other conditions

United States
Gruppo Oncologico Italiano di Ricerca Clinica

Completed

Phase I/II Study to Evaluate Nab-paclitaxel in Substitution of CPT11 or Oxaliplatin in FOLFIRINOX Schedule as First Line Treatment in Metastatic Pancreatic Cancer (NabucCO)

Metastatic Pancreatic Cancer

Italy
China Medical University, China

Recruiting

Clinical Study of Nab-paclitaxel Combined With Toripalimab in Local Advanced or Metastatic G/GEJ Carcinoma

Gastric Carcinoma

China
Cancer Institute and Hospital, Chinese Academy...

Terminated

First Line Chemotherapy for Advanced Cancer (GC-A-003)

Gastric Cancer

China
Huazhong University of Science and Technology
CSPC Ouyi Pharmaceutical Co., Ltd.

Recruiting

Albumin-bound Paclitaxel Plus S-1 Versus SOX as First-line Treatment in Advanced or Recurrent Gastric Adenocarcinoma

Gastric Cancer

China
Cancer Institute and Hospital, Chinese Academy...

Unknown

Clinical Study of Albumin-bound Paclitaxel Plus Nedaplatin in Cervical Cancer (CSAPPPCC)

Uterine Cervical Cancer

China
Fudan University

Not yet recruiting

QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk TNBC Breast Cancer (QUEEN-Dream)

Neoadjuvant Therapy | Early Breast Cancer | TNBC, Triple Negative Breast Cancer

China
Peking University
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Not yet recruiting

Anlotinib, TQB2450 (PD-L1 Inhibitor), and Albumin-bound Paclitaxel Regimens in the Treatment of GC/GEJA

Gastric Cancer | Adenocarcinoma of Esophagogastric Junction

China
Second Affiliated Hospital, School of Medicine,...

Recruiting

Neoadjuvant Therapy of Sintilimab Combined With Chemotherapy for Resectable Squamous Cell NSCLC（neoSCORE Ⅱ） (neoSCORE Ⅱ)

Squamous Cell Non-small Cell Lung Cancer

China
Chinese PLA General Hospital

Unknown

Nab-paclitaxel Plus S-1 in Patients With Advanced Pancreatic Cancer (NAPSPAC)

Advanced Pancreatic Cancer

China
Tang-Du Hospital

Active, not recruiting

Camrelizumab Combined With Albumin-bound Paclitaxel and Platinum in Neoadjuvant Treatment of Resectable NSCLC

Non-small-cell Lung Cancer (NSCLC)

China
Fujian Cancer Hospital
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Recruiting

PD-1 Inhibitor Combined With Neoadjuvant Chemotherapy in Subjects With Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma (REVO)

Esophageal Neoplasms | Esophageal Squamous Cell Carcinoma

China
Emory University
National Cancer Institute (NCI)

Active, not recruiting

Paricalcitol and Hydroxychloroquine in Combination With Gemcitabine and Nab-Paclitaxel for Advanced Pancreatic Cancer

Stage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Adenocarcinoma | Advanced Pancreatic Adenocarcinoma

United States
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Not yet recruiting

Effect of Albumin-bound Paclitaxel Plus Carboplatin Compared With Paclitaxel Plus Carboplatin in Patients Receiving Neoadjuvant Chemotherapy for Advanced Ovarian, Fallopian Tube or Peritoneal Cancer: A Phase 2 Single Center Clinical Trial

Ovarian Cancer
Zhejiang Cancer Hospital
CSPC Ouyi Pharmaceutical Co., Ltd.

Recruiting

Nab-paclitaxel Combined With S-1 as Adjuvant Chemotherapy for Stage Ⅲ Gastric Cancer

Stomach Cancer

China
The Affiliated Nanjing Drum Tower Hospital of Nanjing...

Not yet recruiting

The Paclitaxel (Albumin-bound) Combined With Cisplatin, PD-1 Inhibitors and IMRT in the Treatment of Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma
Tianjin Medical University Cancer Institute and...

Recruiting

Efficacy and Safety of SHR-1020 Combined With Albumin-bound Paclitaxel in the Second-line Treatment of Pancreatic Cancer

Pancreatic Cancer

China
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer

Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Unresectable Pancreatic Carcinoma

United States
Mayo Clinic
National Cancer Institute (NCI)

Withdrawn

Cryoablation, Atezolizumab/Nab-paclitaxel for Locally Advanced or Metastatic Triple Negative Breast Cancer

Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Anatomic Stage IIIB Breast Cancer AJCC v8 | Anatomic Stage IIIC Breast Cancer AJCC v8 | Prognostic Stage III Breast Cancer AJCC v8 | Prognostic Stage IIIA Breast Cancer AJCC v8 | Prognostic Stage IIIB Breast... and other conditions
M.D. Anderson Cancer Center

Active, not recruiting

Nab-Paclitaxel and Atezolizumab Before Surgery in Treating Patients With Triple Negative Breast Cancer

Invasive Breast Carcinoma | Triple-Negative Breast Carcinoma | Breast Adenocarcinoma

United States
Celgene

Completed

A Safety Study of ABI-007 for In-Stent Restenosis

Coronary Artery Disease | Angina Pectoris

United States
Yuhong Li

Completed

S-1 in Combination With Abraxane in Treating Cholangiocarcinoma

Cholangiocarcinoma

China
Lee's Pharmaceutical Limited

Active, not recruiting

A Study of Anti-PD-L1 Antibody in Neoadjuvant Chemotherapy of Esophageal Squamous Cell Carcinoma.

Esophageal Cancer

China
Junling Li

Unknown

Efficacy and Safety of IBI308 and Paclitaxel/Albumin Paclitaxel for SCLC Patients Who Failed Etoposide Chemotherapy

Extensive-Stage Small Cell Lung Cancer

China
Zhejiang University

Unknown

Neoadjuvant Chemotherapy of Nanoparticle Albumin-bound Paclitaxel in Lung Cancer

Non Small Cell Lung Cancer

China
University of Michigan Rogel Cancer Center
Celgene Corporation

Terminated

Trial of Combination ABI-007, Carboplatin, and Gemcitabine for First Line Treatment of Advanced Urothelial Cancer

Bladder Cancer | Urothelial Cancer

United States
Muhammad Furqan
Celgene Corporation

Active, not recruiting

Nab-Paclitaxel With Gemcitabine for Relapsed Small Cell Cancer

Small Cell Lung Cancer (SCLC)

United States
Tongji Hospital
Zhejiang Cancer Hospital; Xiangya Hospital of Central South University; Beijing... and other collaborators

Not yet recruiting

Neoadjuvant Immunochemotherapy in PD-L1-negative LACC

Cervical Cancer | Locally Advanced Cervical Cancer | PD-L1 Negative | Neoadjuvant Chemoimmunotherapy

China

Search clinical trials for: anti-PD-1 Albumin-Bound Paclitaxel

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Slovakia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations